ACTIVE

PHARMA 310505

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result28,9 k €+11,9 %over 1 year
Gross margin110,5 k €+2,2 %over 1 year
Equity413,1 k €+391,0 %over 1 year
Workforce0,0 ETP

Identity

Source · BCE/KBO

PHARMA 310505 is a Private limited company incorporated in 2015. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Brugge.

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0643.802.856
Incorporation
02/12/2015
Legal form
Private limited company
Registered office
Koolkerkse Steenweg 150
8000 Brugge · FlandreSee on map
Contributed capital
318 600,00 €
Latest accounts
31/12/2025
Average workforce
0,0 ETP
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDA

Financials

Source · NBB, 10 filings

Trend over 8 financial years

20252024202320222021
Income statement
Gross margin110,5 k €108 k €103,9 k €96 k €89,7 k €
EBITDA108,6 k €106,9 k €102,8 k €94,6 k €88,6 k €
Operating result37,6 k €35,9 k €31,8 k €23,6 k €15,6 k €
Net result28,9 k €25,9 k €21,5 k €14,2 k €6,7 k €
Balance sheet
Equity413,1 k €84,1 k €58,3 k €36,7 k €22,6 k €
Total assets1,1 M €270,8 k €314,9 k €364,2 k €414,9 k €
Cash409,1 k €6,9 k €6,5 k €6,9 k €7,1 k €
Debts665,2 k €186,4 k €256,3 k €327 k €391,7 k €
Other
Workforce0,0 ETP––––

Valuation

Indicative valuation

As an indication, this company is worth

between 500 k€ and 1 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 3 ended

Active mandates

Ampuls

Director · since 01 janvier 2026 · 1030.912.238

Represented by Marie Clyncke

Active
Strybol Iben Pharma

Director · since 01 janvier 2026 · 0766.610.695

Represented by Strybol Iben

Active
Strybol Wout Pharma

Director · since 01 janvier 2026 · 0712.514.587

Represented by Strybol Wout

Active

Ended mandates

Filip Taveirne

Manager · since 02 décembre 2015

Ended
Filip Taveirne

Director

Ended
Filip Taveirne

Manager

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelMicro modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date02/07/202622/05/202511/07/202406/07/202301/06/202231/08/2021
General meeting24/06/202627/04/202515/06/202417/06/202328/05/202230/06/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 10 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202524/06/202602/07/2026DutchPDF
Abridged model31/12/202427/04/202522/05/2025DutchPDF
Abridged model31/12/202315/06/202411/07/2024DutchPDF
Micro model31/12/202217/06/202306/07/2023DutchPDF
Abridged model31/12/202128/05/202201/06/2022DutchPDF
Abridged model31/12/202030/06/202131/08/2021DutchPDF
Abridged model31/12/201930/06/202031/08/2020DutchPDF
Abridged model31/12/201815/06/201904/07/2019DutchPDF
Abridged model31/12/201730/06/201829/08/2018DutchPDF
Abridged model31/12/201624/06/201727/06/2017DutchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 500 k€ and 1 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

3 active · 3 ended

Active mandates

Ampuls

Director · since 01 janvier 2026 · 1030.912.238

Represented by Marie Clyncke

Active
Strybol Iben Pharma

Director · since 01 janvier 2026 · 0766.610.695

Represented by Strybol Iben

Active
Strybol Wout Pharma

Director · since 01 janvier 2026 · 0712.514.587

Represented by Strybol Wout

Active

Ended mandates

Filip Taveirne

Manager · since 02 décembre 2015

Ended
Filip Taveirne

Director

Ended
Filip Taveirne

Manager

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates09/01/2026
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - DIVERSEN - DOEL - KAPITAAL - AANDELEN - ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
    PDF
  • Mandates28/06/2022
    STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, …) - WIJZIGING RECHTSVORM - DIVERSEN - ONTSLAGEN - BENOEMINGEN
    PDF
  • Other11/12/2015
    RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 202528,9 k €↑
  2. 2024
    Annual accounts 202425,9 k €↑
  3. 2023
    Annual accounts 202321,5 k €↑
  4. 2022
    Annual accounts 202214,2 k €↑
  5. 2021
    Annual accounts 20216,7 k €↑
  6. 2018
    Annual accounts 20181,4 k €↑
  7. 2017
    Annual accounts 2017-16,7 k €↓
  8. 2016
    Annual accounts 2016-2,5 k €
  9. 02/12/2015
    IncorporationPrivate limited company